期刊文献+

ET-1在增生性糖尿病性视网膜病变患者血和玻璃体中的表达研究 被引量:1

Study of endothelin-1 expression in vitreous and serum in proliferative diabetic retinopathy
下载PDF
导出
摘要 目的:通过定量检测内皮素1(endothelin-1,ET-1)在增生性糖尿病性视网膜病变(proliferative diabetic retinopathy,PDR)患者血和玻璃体中的表达及其相关性,探索ET-1在PDR的发病机制中的作用。方法 :本研究共纳入需行玻璃体切除术的患者65例71眼,分为PDR组及对照组,记录所有患者年龄、性别、身高、体重、病史、空腹血糖、高密度脂蛋白、低密度脂蛋白、甘油三脂、总胆固醇及糖尿病患者糖尿病病程和糖化血红蛋白等情况。收集所有患者血清和玻璃体,离心后-80℃冰箱冻存,使用酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)检测血清和玻璃体中ET-1的含量。结果:PDR组和对照组年龄、性别比较均无统计学意义(P>0.05)。PDR组血清ET-1浓度1.82(1.16,2.50)pg/ml高于对照组1.21(0.66,1.79)pg/ml(P=0.007);PDR组玻璃体中ET-1浓度5.27(4.03,6.95)pg/ml高于对照组4.19(1.77,5.81)pg/ml(P=0.013)。两组玻璃体中ET-1浓度均高于血中ET-1浓度,两组玻璃体和血中ET-1浓度之间无明显相关性(r PDR组=0.423,PPDR组=0.07;r对照组=-0.19,P对照组=0.601)。PDR组空腹血糖、BMI均较对照组高(P<0.05);PDR组患者糖化血红蛋白明显升高(P=0.000)。结论:PDR患者血和玻璃体中ET-1水平较正常人群升高。PDR可能发生于血脂及BMI正常的糖尿病患者。 Abstruca Objective: This experiment is to investigate the potential role of ET-1 in the pathogenesis of proliferative diabetic retinopathy(PDR) by detecting the expression of ET-1 in vitreous and serum, and the correlation of the concentration of ET-1 in serum and in vitreous was analyzed. Methods: A total of 65 patients who were candidates for conventional pars plana vitrectomy were divided into PDR group and control group. Age,gender, height, weight, history of diabetes, fasting blood glucose, high density lipoprotein, low density lipoprotein,triglyceride, total cholesterol, duration of diabetes, and glycosylated hemoglobin of PDR patients were recorded.All the serum and vitreous samples were collected and spun down, and the supernatants were then frozen at-80 ℃.The concentrations of ET-1 in serum and vitreous were determined by enzyme-linked immunosorbent assay(ELISA). Results: Age and gender difference between the PDR group and control group were not statistically significant(P 0.05). The ET-1 concentration in the serum of the PDR group was higher than that in the control group(P 0.01). The ET-1 concentration in the vitreous of PDR group was higher than that in the control group(P 0.05). Although the concentration of ET-1 in vitreous was increased than that in the serum in the two groups, there was no correlation between vitreous and serum in the two groups(r PDR group = 0.423, P PDR group = 0.075 and control group r control group =-0.19, P control group = 0.601). Fasting blood glucose andBMI in the PDR group were higher than those in the control group(P 0.05). The glycosylated hemoglobin in the PDR group was significantly increased(P 0.01) relative to the control group. Conclusion: The concentration of ET-1in the serum and vitreous of the PDR patient is significant higher than that in normal people. PDR may occur in diabetic patients with normal blood lipid and BMI.
出处 《泸州医学院学报》 2016年第3期223-227,共5页 Journal of Luzhou Medical College
关键词 增生性糖尿病性视网膜病变 内皮素1 血清 玻璃体 血糖 Proliferative diabetic retinopathy Endothelin-1 Serum Vitreous Blood glucose
  • 相关文献

参考文献1

二级参考文献11

  • 1Patel A;MacMahon S;Chalmers J.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,2008.
  • 2UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetesBritish Medical Journal,1998.
  • 3Heart Outcomes Prevention Evaluation Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet . 2000
  • 4CP Wilkinson,FL Ferris,RE Klein,PP Lee,CD Agardh,M Davis.Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology . 2003
  • 5Lunetta M,Infantone L,Calogero AE,Infantone E.Increased urinary albumin excretion is a marker of risk for retinopathy and coronary heart disease in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice . 1998
  • 6Zoungas S,de Galan BE,Ninomiya T,Grobbee D,Hamet P,Heller S,MacMahon S,Marre M,Neal B,Patel A,Woodward M,Chalmers J,ADVANCE Collaborative Group,Cass A,Glasziou P,Harrap S,Lisheng L,Mancia G,Pillai A,Poulter N,Perkovic V,Travert F.Combined effects of routine blood pressure lowering and intensive glucose control onmacrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care . 2009
  • 7Beulens JW,Patel A,Vingerling JR,Cruickshank JK,Hughes AD,Stanton A,Lu J,McG Thom SA,Grobbee DE,Stolk RP.Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia . 2009
  • 8Brito JP,,Montori VM.Intensive BP control and/or glucose control did not reduce microvascular events in hypertensive type 2 diabetes. Annals of Internal Medicine . 2012
  • 9Chew EY,Ambrosius WT,Davis MD,Danis RP,Gangaputra S,Greven CM,Hubbard L,Esser BA,Lovato JF,Perdue LH,Goff DC Jr,Cushman WC,Ginsberg HN,Elam MB,Genuth S,Gerstein HC,Schubart U,Fine LJ.Effects of medical therapies on retinopathy progression in type 2 diabetes. The New England Journal of Medicine . 2010
  • 10Albers JW,Herman WH,Pop-Busui R,Feldman EL,Martin CL,Cleary PA,Waberski BH,Lachin JM.Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care . 2010

共引文献4

同被引文献5

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部